World’s largest clinical trial in pre- and early diabetes utilizes Myriad RBM’s biomarker technology.
Myriad RBM, a subsidiary of Myriad Genetics, recently announced its research collaboration with Sanofi. Protein biomarker research will be performed by Myriad RBM as part of the world’s largest clinical trial in pre-and early diabetes, ORIGIN.
Over 8000 serum samples collected during the ORIGIN clinical trial will be analyzed by Myriad RBM using its DiscoveryMAP® 250+ quantitative immunoassay panel. Population Health Research Institute (PHRI) at Hamilton Health Sciences and McMaster University (Canada) will then analyze the findings by assessing the correlation between the biomarker results and the clinical outcomes.
Craig Benson, President of Myriad RBM, commented, “We are pleased to be partnering with Sanofi and PHRI, world leaders in diabetes research, on this critical study. We believe this collaboration will result in better care for millions of patients with diabetes; a global epidemic that remains a critical unmet medical need.”
The ORIGIN study, funded by Sanofi and directed by PHRI, is a 6-year cardiovascular outcomes trial evaluating Lantus® (insulin gargien) versus standard care. The unique study considered 12,500 individuals at high cardiovascular risk with pre-diabetes or early type 2 diabetes mellitus across 40 countries.
“This biomarker project using DiscoveryMAP is a logical extension of the landmark ORIGIN study. The measurement of hundreds of relevant proteins in metabolic, inflammatory and other important pathways has the potential to improve treatment protocols for diabetes,” stated Matt McQueen, Research Laboratory Director at PHRI.